Day: February 6, 2023

LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay

LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully...

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS...

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb....

HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease

Israeli patent covers a country known as a hotbed for medical device innovationSouthlake, Texas, Feb. 06, 2023 (GLOBE NEWSWIRE) --...

error: Content is protected !!